Triple threat: new combo aims to boost immunotherapy in tough breast cancer
Disease control
Not yet recruiting
This phase 2 trial tests whether adding a targeted drug (axatilimab) and radiation to the immunotherapy pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer who have already tried immunotherapy. About 34 participants will receive all three …
Phase: PHASE2 • Sponsor: Stephen Shiao • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC